Page 17 - Haematologica May 2022

Editorials
line chemotherapy. In the meantime, the retrospective studies by Mei et al. and others provide important bench- marks of outcomes following autoHCT, suggesting that autoHCT remains a reasonable option for the patients with chemosensitive R/R DLBCL, even in later lines of therapy. For those patients, CAR-T can be held in reserve in case of relapse after transplant.
Disclosures
NLB has received personal research funding from KITE/Gilead, has received research funding to the institution from ADC Therapeutics, Bristol-Meyers Squibb, Celgene, Forty Seven, Immune Design, Janssen, KITE Pharma, Merck, Millennium, Pharmacyclics,Pfizer, Roche/Genentech and SeaGen, and sits on the advisory boards of ADC Therapeutics, Roche/Genentech, SeaGen. AFC sits on the advisory board of Secura Bio and has received research funding Secura Bio.
Contributions
AC and NLB contributed equally to the writing of this editorial.
References
1. Mei M, Hamadani M, Ahn K, et al. Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after 3 or more lines of prior therapy: evidence of durable benefit. Haematologica. 2022;105(5):1214-1217.
2.Shah N, Ahn K, Litovich C, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021;137(10):1416-1423.
3.Bal S, Costa L, Suater C, Litovich C, Hamadani M. Outcomes of autologous hematopoietic cell transplantation in diffuse large B cell lymphoma refractory to firstline chemoimmunotherapy. Transplant Cell Ther. 2021;27(1):55.e1-55.e7.
4. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190.
5.Hamadani M, Parameswaran N, Zhang Y, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20 (11):1729-1736.
6.Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail sec- ond-line salvage regimens in the international CORAL study. Bone Marrow Transplant. 2016;51(1):51-57.
7. Locke F, Miklos D, Jacobson C, et al. Axicabtagene ciloleucel as sec- ond-line therapy for large B-cell lymphoma. N Eng J Med. 2022;386 (7):640-654.
8. Bishop M, Dickinson M, Purtill D, et al. Second-line tisagenlecleu- cel or standard care in aggressive B-cell lymphoma. N Eng J Med. 2022;386(7):629-639.
9. Budde L, Assouline S, Sehn L, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022;40(5):481-491
10.Caimi P, Ai W, Alderuccio J, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet. 2021;22 (6):790-800.
haematologica | 2022; 107(5)
1025